Evidence map›Paper›PMID 32337293›Full record

ArticleJournal of diabetes research2020

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.

Yoshiro Fushimi, Atsushi Obata, Junpei Sanada, Yuichiro Iwamoto, Akiko Mashiko, Megumi Horiya, Akiko Mizoguchi-Tomita, Momoyo Nishioka, Yuki Kan, Tomoe Kinoshita and 9 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Yoshiro FushimiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Atsushi ObataDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.ORCID https://orcid.org/0000-0003-4984-4098
Junpei SanadaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Yuichiro IwamotoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Akiko MashikoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Megumi HoriyaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Akiko Mizoguchi-TomitaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Momoyo NishiokaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Yuki KanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Tomoe KinoshitaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Seizo OkauchiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Hidenori HirukawaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.ORCID https://orcid.org/0000-0002-4826-2574
Kenji KoharaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Fuminori TatsumiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Masashi ShimodaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.ORCID https://orcid.org/0000-0002-4223-9613
Shuhei NakanishiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Tomoatsu MuneDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Kohei KakuDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Hideaki KanetoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.ORCID https://orcid.org/0000-0001-7898-1943
Kawasaki Medical School Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness and improvement of patients' adherence. However, it is still poorly understood which factors are related to the efficacy of SGLT2 inhibitors as add-on therapy to DPP-4 inhibitors. Therefore, we aimed to elucidate in which type of individuals and/or under which conditions canagliflozin as add-on therapy to teneligliptin could exert more beneficial effects on glycemic control and/or renal protection. We retrospectively analyzed 56 Japanese subjects with T2DM in the real-world clinical practice. Three months after starting the combination therapy, the change of HbA1c (

Indexed as

AgedBlood GlucoseCanagliflozinDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationFemaleGlucagonGlycated HemoglobinHumansHypoglycemic AgentsJapanMaleMiddle AgedPyrazolesRetrospective Studies3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidineBlood GlucoseCanagliflozinDipeptidyl-Peptidase IV InhibitorsGlucagonGlycated HemoglobinHypoglycemic AgentsPyrazolesSodium-Glucose Transporter 2 InhibitorsThiazolidines

Identifiers

PMID32337293
PMCPMC7154962
OpenAlexW3015179651

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.